BioCardia Receives FDA Acceptance For Its Pre-Submission Package For Marketing Clearance Of Its Helix Catheter For Therapeutic And Diagnostic Agent Delivery

BioCardia, Inc. (NASDAQ: BCDA) announced that the FDA has accepted its pre-submission package for marketing clearance of its Helix catheter, which is designed for therapeutic and diagnostic agent delivery. This development marks a significant step for the company in advancing its product offerings in the cardiovascular and pulmonary disease treatment market.